KR101332058B1 - 칼슘 수용체-활성 화합물을 포함하는, 급속한 용해프로필을 갖는 조성물 - Google Patents

칼슘 수용체-활성 화합물을 포함하는, 급속한 용해프로필을 갖는 조성물 Download PDF

Info

Publication number
KR101332058B1
KR101332058B1 KR1020067003448A KR20067003448A KR101332058B1 KR 101332058 B1 KR101332058 B1 KR 101332058B1 KR 1020067003448 A KR1020067003448 A KR 1020067003448A KR 20067003448 A KR20067003448 A KR 20067003448A KR 101332058 B1 KR101332058 B1 KR 101332058B1
Authority
KR
South Korea
Prior art keywords
composition
weight
delete delete
total weight
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020067003448A
Other languages
English (en)
Korean (ko)
Other versions
KR20070017460A (ko
Inventor
프란시스코 제이 알바레즈
글렌 그레이 로렌스
헝-렌 에이치 린
추치 알 주
Original Assignee
암젠 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34434844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101332058(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 암젠 인코포레이티드 filed Critical 암젠 인코포레이티드
Publication of KR20070017460A publication Critical patent/KR20070017460A/ko
Application granted granted Critical
Publication of KR101332058B1 publication Critical patent/KR101332058B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067003448A 2003-09-12 2004-09-10 칼슘 수용체-활성 화합물을 포함하는, 급속한 용해프로필을 갖는 조성물 Expired - Lifetime KR101332058B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50221903P 2003-09-12 2003-09-12
US?60/502,219? 2003-09-12
PCT/US2004/026732 WO2005034928A1 (en) 2003-09-12 2004-09-10 Rapid dissolution formulation of a calcium receptor-active compound

Publications (2)

Publication Number Publication Date
KR20070017460A KR20070017460A (ko) 2007-02-12
KR101332058B1 true KR101332058B1 (ko) 2013-11-22

Family

ID=34434844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067003448A Expired - Lifetime KR101332058B1 (ko) 2003-09-12 2004-09-10 칼슘 수용체-활성 화합물을 포함하는, 급속한 용해프로필을 갖는 조성물

Country Status (30)

Country Link
US (7) US7829595B2 (enExample)
EP (8) EP2821067B1 (enExample)
JP (3) JP5026077B2 (enExample)
KR (1) KR101332058B1 (enExample)
CN (1) CN1946382B (enExample)
AR (1) AR045637A1 (enExample)
AU (1) AU2004279318C1 (enExample)
BR (2) BRPI0414254B8 (enExample)
CA (1) CA2536487C (enExample)
CY (5) CY1119609T1 (enExample)
DE (1) DE19164145T1 (enExample)
DK (6) DK3260117T3 (enExample)
EA (1) EA013425B1 (enExample)
ES (7) ES2655435T3 (enExample)
HR (1) HRP20130114T4 (enExample)
HU (5) HUE044822T2 (enExample)
IL (1) IL173737A (enExample)
IS (1) IS3027B (enExample)
MX (1) MXPA06002616A (enExample)
MY (1) MY142046A (enExample)
NO (1) NO335739B1 (enExample)
NZ (1) NZ545498A (enExample)
PL (6) PL3395338T3 (enExample)
PT (6) PT3395338T (enExample)
SG (1) SG146608A1 (enExample)
SI (6) SI3395340T1 (enExample)
TR (4) TR201910447T4 (enExample)
TW (1) TWI344363B (enExample)
WO (1) WO2005034928A1 (enExample)
ZA (1) ZA200602710B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
ES2332016T3 (es) * 2005-05-16 2010-01-22 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de hidrocloruro de cinacalcet.
EP1883618B1 (en) * 2005-05-23 2009-10-14 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
JP2008507567A (ja) * 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
CN101184489B (zh) 2005-05-26 2011-01-19 大日本住友制药株式会社 药物组合物
ES2400693T3 (es) * 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
US7563930B2 (en) * 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
TW200811082A (en) * 2006-04-27 2008-03-01 Teva Pharma Process for the preparation of cinacalcet base
WO2007127445A2 (en) * 2006-04-27 2007-11-08 Teva Pharmaceutical Industries Ltd. Process for the preparation of cinacalcet base
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
US20090258949A1 (en) * 2006-06-27 2009-10-15 Johannes Ludescher Amorphous form of cinacalcet
US20080181959A1 (en) * 2006-09-01 2008-07-31 Ilan Zalit Solid composites of a calcium receptor-active compound
WO2008064202A2 (en) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Modified-release formulations of calcium receptor-active compounds
WO2008063645A1 (en) * 2006-11-20 2008-05-29 Teva Pharmaceutical Industries Ltd. Process for preparing cinacalcet
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US20080261926A1 (en) * 2007-04-02 2008-10-23 Liu Julie F Pharmaceutical Calcimimetics
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
US20090093652A1 (en) * 2007-08-16 2009-04-09 Michal Rafilovich Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
US20110189241A1 (en) * 2008-05-05 2011-08-04 Medichem, S.A. Process For Controlling The Particle Size of A [3-(Trifluoromethyl)Phenyl]-1-Aminopropane Derivative
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2334284B1 (de) * 2008-09-25 2012-08-08 Ratiopharm GmbH Kompaktiertes cinacalcet
WO2010086129A1 (en) 2009-01-27 2010-08-05 Rathiopharm Gmbh Inclusion complex comprising cinacalcet and cyclodextrin
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
WO2010136035A2 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2314286A1 (de) 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
RS60203B1 (sr) * 2010-11-23 2020-06-30 Amgen Inc Pedijatrijska formulacija
CN103228629A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 作为CaSR活性化合物的被取代的环戊基-氮杂苯类
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
WO2012069420A2 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
JP6145112B2 (ja) 2011-12-19 2017-06-07 アムジエン・インコーポレーテツド 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用
EP2804588B1 (en) 2012-01-17 2017-09-06 Zentiva Saglik Urunleri San. Ve Tic. A.S. Method for producing cinacalcet compositions for direct tableting
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
CN102885792A (zh) * 2012-10-12 2013-01-23 华润赛科药业有限责任公司 盐酸西那卡塞的口服固体速释制剂
PL2730279T3 (pl) * 2012-11-09 2015-12-31 K H S Pharma Holding Gmbh Preparaty cynakalcetu o natychmiastowym uwalnianiu
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
BR112015014430B1 (pt) 2012-12-21 2022-08-30 Synthon B.V. Composição em comprimido
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3013324A1 (en) 2013-06-26 2016-05-04 Jubilant Generics Limited Disintegrant free composition of cinacalcet
EP3116487A1 (en) * 2014-03-14 2017-01-18 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical composition of cinacalcet
WO2015150944A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Solid oral pharmaceutical compositions comprising cinacalcet or a salt thereof
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
CN104721164B (zh) * 2015-03-25 2017-07-07 河北仁合益康药业有限公司 一种盐酸西那卡塞薄膜衣片组合物
WO2017182237A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
US11413295B2 (en) 2016-03-31 2022-08-16 Intercept Pharmaceuticals, Inc. Oral preparation of obeticholic acid
EP3668493A4 (en) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITIONS WITH CINACALCET HYDROCHLORIDE AND ONE OR MORE BINDERS
US20210030671A1 (en) 2018-03-30 2021-02-04 Ftf Pharma Private Limited Liquid dosage forms of cinacalcet or salt thereof
US10920483B2 (en) 2018-10-25 2021-02-16 Mark Mutchnik Window seal for preventing water penetration
RU2750761C2 (ru) * 2019-09-17 2021-07-02 Общество с ограниченной ответственностью "АМЕДАРТ" Ядро таблетки, содержащей цинакальцета гидрохлорид
BR112022017133A2 (pt) * 2020-02-29 2022-10-11 Kempharm Inc Composições compreendendo pró-drogas de metilfenidato, processos de fabricação e uso das mesmas
CN112546010A (zh) * 2020-12-02 2021-03-26 普莱赛思(天津)生命科技有限公司 一种肾病药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211244B1 (en) * 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
EP0315249A1 (en) 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
EP0357815A1 (de) 1988-09-06 1990-03-14 Siemens Aktiengesellschaft Schaltbare Konstantstromquelle mit I2L-Gattern
EP0373417A1 (en) 1988-11-30 1990-06-20 Schering Corporation Sustained release diltiazem formulation
NZ231897A (en) * 1988-12-30 1992-09-25 Monsanto Co Dry water-soluble granular composition comprising glyphosate and a liquid surfactant
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US4931286A (en) 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
DD299322A5 (de) * 1989-09-21 1992-04-09 Maschinenfabrik Rieter Ag,Ch Verfahren und vorrichtung zur feinreinigung von textilfasern
US5011068A (en) * 1989-12-05 1991-04-30 Progressive Tool & Industries Co. Automotive body framing system
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE312347T1 (de) 1991-08-23 2005-12-15 Nps Pharma Inc Screening-verfahren für kalzium-rezeptor aktive verbindungen
US6313146B1 (en) * 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995011221A1 (en) 1991-08-23 1995-04-27 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
ATE267009T1 (de) 1993-02-23 2004-06-15 Brigham & Womens Hospital Calciumrezeptoraktive moleküle
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
GB9424766D0 (en) 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9501127D0 (en) 1995-01-20 1995-03-08 Wellcome Found Tablet
DE19530575A1 (de) 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
EP0907631B1 (en) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US5837292A (en) 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
AU734710B2 (en) 1996-07-08 2001-06-21 Kyowa Hakko Kirin Co., Ltd. Calcium receptor active compounds
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
WO1999009458A1 (de) 1997-08-13 1999-02-25 OCé PRINTING SYSTEMS GMBH Druck- oder kopiergerätesystem zum performanceangepassten erstellen einer vorgegebenen blattfolge von monochrom und/oder farbig bedruckten einzelblättern
DE69901938T3 (de) 1998-03-06 2012-08-02 Aptalis Pharma S.R.L. Schnell zerfallende tablette
US6525084B2 (en) 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
JP2002527414A (ja) 1998-10-14 2002-08-27 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド １，２−ジ置換シクロプロパン
NZ511850A (en) * 1998-11-23 2003-11-28 Monsanto Co Highly concentrated aqueous glyphosate compositions
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6447809B1 (en) * 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
AU2731401A (en) * 1999-12-22 2001-07-03 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
AU2001288102A1 (en) 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
IN191028B (enExample) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
WO2003000294A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1321142A1 (en) 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
AU2003238670A1 (en) 2002-04-05 2003-10-27 Cadila Healthcare Limited Fast disintegrating oral dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
WO2004030669A1 (en) 2002-09-30 2004-04-15 Schering Corporation Use of tricyclic amides for the treatment of disorders of calcium homeostasis
GB0230015D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
KR20070043043A (ko) 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
NL1028867C2 (nl) 2005-04-26 2006-10-27 Xycarb Ceramics B V Inrichting voor het ondersteunen van een substraat alsmede een werkwijze voor het vervaardigen van een dergelijke inrichting.
CA2717906C (en) 2008-03-11 2022-07-05 Jamu Alford System and method for magnetic resonance imaging

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211244B1 (en) * 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds

Also Published As

Publication number Publication date
US20050147669A1 (en) 2005-07-07
NO20061640L (no) 2006-06-12
DK3395340T3 (da) 2019-07-15
TW200518743A (en) 2005-06-16
EP3395340B1 (en) 2019-04-17
DK1663182T4 (da) 2020-02-17
EP3395340A1 (en) 2018-10-31
JP2015007089A (ja) 2015-01-15
CA2536487C (en) 2011-10-25
US20160338975A1 (en) 2016-11-24
ES2735216T3 (es) 2019-12-17
ES2735226T3 (es) 2019-12-17
HRP20130114T4 (hr) 2019-12-27
HUE043958T2 (hu) 2019-09-30
TR201910447T4 (tr) 2019-08-21
PT1663182E (pt) 2013-03-14
IL173737A (en) 2012-04-30
ZA200602710B (en) 2007-04-25
EP2316442A1 (en) 2011-05-04
ES2655435T3 (es) 2018-02-20
JP5849015B2 (ja) 2016-01-27
US20210052518A1 (en) 2021-02-25
TR201910180T4 (tr) 2019-07-22
HUE045411T2 (hu) 2019-12-30
IS3027B (is) 2021-03-15
MY142046A (en) 2010-08-30
ES2401769T3 (es) 2013-04-24
US20190117592A1 (en) 2019-04-25
MXPA06002616A (es) 2006-06-05
BR122018013029B1 (pt) 2022-04-12
SG146608A1 (en) 2008-10-30
US9375405B2 (en) 2016-06-28
US7829595B2 (en) 2010-11-09
EP1663182B1 (en) 2013-01-16
EP3578175A1 (en) 2019-12-11
KR20070017460A (ko) 2007-02-12
DK3260117T3 (da) 2019-07-01
AU2004279318B2 (en) 2010-02-25
BRPI0414254B1 (pt) 2021-03-02
EP3578175B1 (en) 2022-11-30
ES2734057T3 (es) 2019-12-04
AU2004279318C1 (en) 2020-06-25
TR201909267T4 (tr) 2019-07-22
HUE035596T2 (en) 2018-05-28
CN1946382B (zh) 2010-12-08
US20200222340A1 (en) 2020-07-16
SI2821067T1 (en) 2018-03-30
ES2401769T5 (es) 2020-07-01
ES2812198T1 (es) 2021-03-16
CY1121820T1 (el) 2020-07-31
JP5940120B2 (ja) 2016-06-29
CY1121814T1 (el) 2020-07-31
PT3395339T (pt) 2019-07-15
SI1663182T1 (sl) 2013-05-31
PT3260117T (pt) 2019-07-04
EP3395340B8 (en) 2019-12-11
PT3395338T (pt) 2019-07-23
PL2821067T3 (pl) 2018-02-28
EP1663182A1 (en) 2006-06-07
PL1663182T3 (pl) 2013-06-28
SI3395340T1 (sl) 2019-08-30
PL3260117T3 (pl) 2019-10-31
SI3395338T1 (sl) 2019-08-30
EP3395338B1 (en) 2019-05-01
DK3395338T3 (da) 2019-07-22
PL3395339T3 (pl) 2019-09-30
SI1663182T2 (sl) 2020-02-28
EP3395339B8 (en) 2019-12-11
EA200600566A1 (ru) 2006-08-25
BRPI0414254B8 (pt) 2021-05-25
TR201910177T4 (tr) 2019-08-21
EP3395339B1 (en) 2019-04-17
IS8324A (is) 2006-02-23
CA2536487A1 (en) 2005-04-21
CN1946382A (zh) 2007-04-11
EP3260117B8 (en) 2019-11-27
US20110136915A1 (en) 2011-06-09
DK1663182T3 (da) 2013-04-15
EP3395338A1 (en) 2018-10-31
US20180243238A1 (en) 2018-08-30
CY1121812T1 (el) 2020-07-31
EA013425B1 (ru) 2010-04-30
IL173737A0 (en) 2006-07-05
NZ545498A (en) 2010-04-30
JP2007505108A (ja) 2007-03-08
EP3260117B1 (en) 2019-04-17
EP3395339A1 (en) 2018-10-31
EP2821067B1 (en) 2017-10-25
ES2737348T3 (es) 2020-01-13
EP3260117A1 (en) 2017-12-27
EP1663182B2 (en) 2019-11-20
DK3395339T3 (da) 2019-07-22
PT2821067T (pt) 2017-12-01
CY1119609T1 (el) 2018-04-04
SI3260117T1 (sl) 2019-08-30
AU2004279318A1 (en) 2005-04-21
DE19164145T1 (de) 2021-04-29
HUE044822T2 (hu) 2019-11-28
NO335739B1 (no) 2015-02-02
HUE044279T2 (hu) 2019-10-28
BRPI0414254A (pt) 2006-11-07
CY1122259T1 (el) 2020-11-25
PL1663182T5 (pl) 2020-07-27
AR045637A1 (es) 2005-11-02
SI3395339T1 (sl) 2019-08-30
TWI344363B (en) 2011-07-01
PT3395340T (pt) 2019-07-15
PL3395338T3 (pl) 2019-10-31
DK2821067T3 (en) 2017-12-04
HRP20130114T1 (xx) 2013-03-31
PL3395340T3 (pl) 2019-10-31
EP2821067A1 (en) 2015-01-07
JP2012197280A (ja) 2012-10-18
JP5026077B2 (ja) 2012-09-12
WO2005034928A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
KR101332058B1 (ko) 칼슘 수용체-활성 화합물을 포함하는, 급속한 용해프로필을 갖는 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090722

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110511

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20120430

Patent event code: PE09021S02D

AMND Amendment
E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20130423

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20121130

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20111111

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130426

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120430

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20110511

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130729

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130426

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130904

Appeal identifier: 2013101005637

Request date: 20130729

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20130729

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20130729

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20121130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20111111

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20130904

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20130902

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20131115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20131115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20160311

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20131115

Comment text: Registration of Establishment

Request date: 20160311

Appeal identifier: 2016100000641

Appeal kind category: Confirmation of the scope of right_defensive

FPAY Annual fee payment

Payment date: 20161019

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20161019

Start annual number: 4

End annual number: 4

J301 Trial decision

Free format text: TRIAL NUMBER: 2016100000641; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160311

Effective date: 20170321

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20170321

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20160311

Decision date: 20170321

Appeal identifier: 2016100000641

FPAY Annual fee payment

Payment date: 20171018

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20171018

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20181018

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20211015

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20221025

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20231023

Start annual number: 11

End annual number: 11

PC1801 Expiration of term

Termination date: 20250310

Termination category: Expiration of duration